Physician profile
Andrew Smith
NPI 1083660880
$11,994.27
in general payments reported to CMS, 2019-2025
53 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,398 · 2020: $1,338 · 2021: $1,878 · 2022: $2,191 · 2023: $1,979 · 2024: $1,580 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,768 · Consulting Fee: $403 · Education: $18.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,767.63 |
| Consulting Fee | $402.67 |
| Education | $18.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,656.82 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,541.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,503.25 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $1,100.17 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amarin Pharma, INC. | $624.96 | 2019-2022 | |
| Amgen INC. | $586.31 | 2019-2025 | Otezla, Repatha, Otezla |
| Jazz Pharmaceuticals INC. | $512.25 | 2021-2025 | Epidiolex |
| Bayer Healthcare Pharmaceuticals INC. | $388.88 | 2022-2025 | |
| Pfizer INC. | $352.73 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.75 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $276.07 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $270.25 | 2019-2024 | Trintellix |
| Esperion Therapeutics, INC. | $217.81 | 2020-2025 | Nexletol |
| Axsome Therapeutics, INC. | $213.60 | 2023-2025 | Sunosi, Auvelity |
| Biohaven Pharmaceuticals, INC. | $212.78 | 2021 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.